Core Viewpoint - Juzi Bio (02367) has seen a rebound of over 8%, with a current price of HKD 41.9 and a trading volume of HKD 400 million, following the announcement of share purchases by its controlling shareholder, Juzi Holding [1] Group 1: Shareholder Activity - Juzi Holding purchased 500,000 shares of Juzi Bio on the announcement date, amounting to approximately HKD 19.3 million [1] - Since the disclosure of the share purchase plan on June 9, 2025, Juzi Holding has cumulatively acquired 3.666 million shares, investing a total of about HKD 178 million [1] - Following these purchases, Juzi Holding's shareholding increased to 585 million shares, representing 54.61% of the company's total issued shares, with intentions to further increase holdings based on market conditions and regulatory requirements [1] Group 2: Market Analysis - Citigroup recently released a report indicating that the market's reaction to Juzi Bio's pre-sale performance decline during the Double 11 event, particularly in relation to Li Jiaqi's live-streaming sales, is exaggerated [1] - Although Li Jiaqi's live-streaming sales trends are significant indicators for Double 11 performance, the contribution from other KOLs and the company's own live-streaming efforts has sharply increased, reducing Li Jiaqi's relative impact [1] - Despite the competitive landscape, there has been no negative feedback from customers regarding the company's products or brand, and Citigroup anticipates a recovery in sales for Juzi Bio in the fiscal year 2026, given the low base this year, suggesting that the company's valuation remains attractive [1]

Core Viewpoint - Juzi Biotechnology (02367) experienced a rebound of over 8%, with a current price of HKD 41.9 and a trading volume of HKD 400 million [1] Group 1: Shareholder Activity - Juzi Holding, the controlling shareholder, purchased 500,000 shares of the company on the announcement date, amounting to approximately HKD 19.3 million [1] - Since the disclosure of the buyback plan on June 9, 2025, Juzi Holding has cumulatively acquired 3.666 million shares, investing a total of about HKD 178 million [1] - Following these purchases, Juzi Holding's shareholding increased to 585 million shares, representing 54.61% of the company's total issued shares, with intentions to further increase holdings based on market conditions and regulatory requirements [1] Group 2: Market Analysis - Citigroup recently released a report indicating that the market's reaction to Juzi Biotechnology's pre-sale performance decline during the Double 11 event, particularly in Li Jiaqi's live-streaming sales, is overly pessimistic [1] - Although Li Jiaqi's live-streaming sales are a significant indicator for Double 11 performance, the contribution from other KOLs and the company's own live-streaming efforts has been rapidly increasing, reducing reliance on any single influencer [1] - Despite the competitive landscape, there has been no negative feedback from customers regarding the company's products or brand [1] - Given the low base this year, Citigroup anticipates a recovery in sales for Juzi Biotechnology in the fiscal year 2026, maintaining that the company's valuation remains attractive [1]